Eric D. Huseman
Research Subjects
Eric D. Huseman has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Seth B. Herzon
Yale University
3 shared publications - Steven D. Townsend
Vanderbilt University
3 shared publications - Anna Marie Pyle
Department of Molecular, Cellular, and Developmental Biology, Yale University, New Haven, CT, USA
2 shared publications - Fabian S. Menges
Department of Chemistry
2 shared publications - Jason M. Crawford
Department of Chemistry, Yale University, New Haven, USA
2 shared publications - Joonseok Oh
Yale University
2 shared publications
Latest Publications
- Open Access
- 4 September 2026
- Published by American Chemical Society (ACS) in ChemRxiv
1º Non-Anomeric Glycoboranes: Palladium Catalyzed Synthesis and Functionalization
The proliferation of methods for transforming the carbon–boron bond has made alkyl organoboranes prized intermediates in organic chemistry. Despite this versatility, the synthesis of borylated carbohydrates (i.e., “glycoboranes”) is largely limited to borylation at the anomeric position or chemistries that leverage glycals to introduce boron at C2 or C3. Herein, we describe a Pd-catalyzed, deiodinative borylation that installs a pinacol boronic ester moiety at the primary position of carbohydrates most distal to the anomeric center to afford 1º non-anomeric glycoboranes. Variously protected glucose, galactose, and mannose scaffolds as well as partially unprotected sugars and di- and trisaccharide substrates readily underwent borylation on millimole scale under these conditions. To demonstrate their utility as functionalizable intermediates, we developed a C( sp 2 )–C( sp 3 ) Suzuki coupling of these 1º non-anomeric glycoboranes. Exploration of the electrophile scope showed generality across a variety of aryl and heteroaryl bromides, including challenging pyridyl and unprotected indole electrophiles as well as four tripeptides containing a (hetero)aryl bromide-functionalized amino acid residue. Taken together, this work illustrates the viability of 1º non-anomeric glycoboranes as intermediates in the synthesis of functionalized glycosides and unnatural glycopeptides.
- 4 September 2026
- Published by American Chemical Society (ACS) in ChemRxiv
Open Access1º Non-Anomeric Glycoboranes: Palladium Catalyzed Synthesis and Functionalization
The proliferation of methods for transforming the carbon–boron bond has made alkyl organoboranes prized intermediates in organic chemistry. Despite this versatility, the synthesis of borylated carbohydrates (i.e., “glycoboranes”) is largely limited to borylation at the anomeric position or chemistries that leverage glycals to introduce boron at C2 or C3. Herein, we describe a Pd-catalyzed, deiodinative borylation that installs a pinacol boronic ester moiety at the primary position of carbohydrates most distal to the anomeric center to afford 1º non-anomeric glycoboranes. Variously protected glucose, galactose, and mannose scaffolds as well as partially unprotected sugars and di- and trisaccharide substrates readily underwent borylation on millimole scale under these conditions. To demonstrate their utility as functionalizable intermediates, we developed a C( sp 2 )–C( sp 3 ) Suzuki coupling of these 1º non-anomeric glycoboranes. Exploration of the electrophile scope showed generality across a variety of aryl and heteroaryl bromides, including challenging pyridyl and unprotected indole electrophiles as well as four tripeptides containing a (hetero)aryl bromide-functionalized amino acid residue. Taken together, this work illustrates the viability of 1º non-anomeric glycoboranes as intermediates in the synthesis of functionalized glycosides and unnatural glycopeptides.
- 30 May 2024
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 146 (27) , 18241-18252
Mechanism of Action of KL-50, a Candidate Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers
Aberrant DNA repair is a hallmark of cancer, and many tumors display reduced DNA repair capacities that sensitize them to genotoxins. Here, we demonstrate that the differential DNA repair capacities of healthy and transformed tissue may be exploited to obtain highly selective chemotherapies. We show that the novel N3-(2-fluoroethyl)imidazotetrazine "KL-50" is a selective toxin toward tumors that lack the DNA repair protein O6-methylguanine-DNA-methyltransferase (MGMT), which reverses the formation of O6-alkylguanine lesions. We establish that KL-50 generates DNA interstrand cross-links (ICLs) by a multistep process comprising DNA alkylation to generate an O6-(2-fluoroethyl)guanine (O6FEtG) lesion, slow unimolecular displacement of fluoride to form an N1,O6-ethanoguanine (N1,O6EtG) intermediate, and ring-opening by the adjacent cytidine. The slow rate of N1,O6EtG formation allows healthy cells expressing MGMT to reverse the initial O6FEtG lesion before it evolves to N1,O6EtG, thereby suppressing the formation of toxic DNA-MGMT cross-links and reducing the amount of DNA ICLs generated in healthy cells. In contrast, O6-(2-chloroethyl)guanine lesions produced by agents such as lomustine and the N3-(2-chloroethyl)imidazotetrazine mitozolomide rapidly evolve to N1,O6EtG, resulting in the formation of DNA-MGMT cross-links and DNA ICLs in healthy tissue. These studies suggest that careful consideration of the rates of chemical DNA modification and biochemical DNA repair may lead to the identification of other tumor-specific genotoxic agents.
- 30 May 2024
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 146 (27) , 18241-18252
Mechanism of Action of KL-50, a Candidate Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers
Aberrant DNA repair is a hallmark of cancer, and many tumors display reduced DNA repair capacities that sensitize them to genotoxins. Here, we demonstrate that the differential DNA repair capacities of healthy and transformed tissue may be exploited to obtain highly selective chemotherapies. We show that the novel N3-(2-fluoroethyl)imidazotetrazine "KL-50" is a selective toxin toward tumors that lack the DNA repair protein O6-methylguanine-DNA-methyltransferase (MGMT), which reverses the formation of O6-alkylguanine lesions. We establish that KL-50 generates DNA interstrand cross-links (ICLs) by a multistep process comprising DNA alkylation to generate an O6-(2-fluoroethyl)guanine (O6FEtG) lesion, slow unimolecular displacement of fluoride to form an N1,O6-ethanoguanine (N1,O6EtG) intermediate, and ring-opening by the adjacent cytidine. The slow rate of N1,O6EtG formation allows healthy cells expressing MGMT to reverse the initial O6FEtG lesion before it evolves to N1,O6EtG, thereby suppressing the formation of toxic DNA-MGMT cross-links and reducing the amount of DNA ICLs generated in healthy cells. In contrast, O6-(2-chloroethyl)guanine lesions produced by agents such as lomustine and the N3-(2-chloroethyl)imidazotetrazine mitozolomide rapidly evolve to N1,O6EtG, resulting in the formation of DNA-MGMT cross-links and DNA ICLs in healthy tissue. These studies suggest that careful consideration of the rates of chemical DNA modification and biochemical DNA repair may lead to the identification of other tumor-specific genotoxic agents.
- Open Access
- 13 June 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Mechanism of Action of KL-50, a Novel Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers
Glioblastoma (GBM) is a lethal brain cancer with a five-year survival rate of 10-fold more slowly from O6FEtG than O6ClEtG, and this slower rate of cross-linking allows MGMT to reverse the initial O6FEtG in healthy tissue while also reducing MGMT–DNA cross-links arising from addition of MGMT to the N1,O6EtG intermediate. KL- 50 is efficacious in an intracranial patient-derived murine xenograft of TMZ-resistant, MGMT–/MMR– GBM (mOS = 205, 28, and 26 d for KL-50, TMZ, and vehicle-treated control, respectively) and in murine models of newly-diagnosed MGMT–/MMR+ GBM, suggesting its use in recurrent and up-front settings, respectively. These studies underscore the significance of considering the rates of chemical DNA modification and biochemical DNA repair in the design of systemic DNA alkylation agents.
- 13 June 2023
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessMechanism of Action of KL-50, a Novel Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers
Glioblastoma (GBM) is a lethal brain cancer with a five-year survival rate of 10-fold more slowly from O6FEtG than O6ClEtG, and this slower rate of cross-linking allows MGMT to reverse the initial O6FEtG in healthy tissue while also reducing MGMT–DNA cross-links arising from addition of MGMT to the N1,O6EtG intermediate. KL- 50 is efficacious in an intracranial patient-derived murine xenograft of TMZ-resistant, MGMT–/MMR– GBM (mOS = 205, 28, and 26 d for KL-50, TMZ, and vehicle-treated control, respectively) and in murine models of newly-diagnosed MGMT–/MMR+ GBM, suggesting its use in recurrent and up-front settings, respectively. These studies underscore the significance of considering the rates of chemical DNA modification and biochemical DNA repair in the design of systemic DNA alkylation agents.
- Top Cited Papers
- 28 July 2022
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 377 (6605) , 502-511
Mechanism-based design of agents that selectively target drug-resistant glioma
Approximately half of glioblastoma and more than two-thirds of grade II and III glioma tumors lack the DNA repair protein O 6 -methylguanine methyl transferase (MGMT). MGMT-deficient tumors respond initially to the DNA methylation agent temozolomide (TMZ) but frequently acquire resistance through loss of the mismatch repair (MMR) pathway. We report the development of agents that overcome this resistance mechanism by inducing MMR-independent cell killing selectively in MGMT-silenced tumors. These agents deposit a dynamic DNA lesion that can be reversed by MGMT but slowly evolves into an interstrand cross-link in MGMT-deficient settings, resulting in MMR-independent cell death with low toxicity in vitro and in vivo. This discovery may lead to new treatments for gliomas and may represent a new paradigm for designing chemotherapeutics that exploit specific DNA repair defects.
- 28 July 2022
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 377 (6605) , 502-511
Top Cited PapersMechanism-based design of agents that selectively target drug-resistant glioma
Approximately half of glioblastoma and more than two-thirds of grade II and III glioma tumors lack the DNA repair protein O 6 -methylguanine methyl transferase (MGMT). MGMT-deficient tumors respond initially to the DNA methylation agent temozolomide (TMZ) but frequently acquire resistance through loss of the mismatch repair (MMR) pathway. We report the development of agents that overcome this resistance mechanism by inducing MMR-independent cell killing selectively in MGMT-silenced tumors. These agents deposit a dynamic DNA lesion that can be reversed by MGMT but slowly evolves into an interstrand cross-link in MGMT-deficient settings, resulting in MMR-independent cell death with low toxicity in vitro and in vivo. This discovery may lead to new treatments for gliomas and may represent a new paradigm for designing chemotherapeutics that exploit specific DNA repair defects.
- Open Access
- 22 July 2021
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 7 (8) , 1327-1337
Synthesis and Cytotoxic Evaluation of Arimetamycin A and Its Daunorubicin and Doxorubicin Hybrids
- 22 July 2021
- Published by American Chemical Society (ACS) in ACS Central Science
- Vol. 7 (8) , 1327-1337
Open AccessSynthesis and Cytotoxic Evaluation of Arimetamycin A and Its Daunorubicin and Doxorubicin Hybrids
- 1 June 2021
- Published by Elsevier in Tetrahedron Letters
- Vol. 73
De novo synthesis of an l-lemonose thioglycoside donor from d-Threonine
- 1 June 2021
- Published by Elsevier in Tetrahedron Letters
- Vol. 73
De novo synthesis of an l-lemonose thioglycoside donor from d-Threonine
- 17 January 2018
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 9 (10) , 2307-2330
The DARK Side of Total Synthesis: Strategies and Tactics in Psychoactive Drug Production
Humankind has used and abused psychoactive drugs for millennia. Formally, a psychoactive drug is any agent that alters cognition and mood. The term “psychotropic drug” is neutral and describes the entire class of substrates, licit and illicit, of interest to governmental drug policy. While these drugs are prescribed for issues ranging from pain management to anxiety, they are also used recreationally. In fact, the current opioid epidemic is the deadliest drug crisis in American history. While the topic is highly politicized with racial, gender, and socioeconomic elements, there is no denying the toll drug mis- and overuse is taking on this country. Overdose, fueled by opioids, is the leading cause of death for Americans under 50 years of age, killing ca. 64,000 people in 2016. From a chemistry standpoint, the question is in what ways, if any, did organic chemists contribute to this problem? In this targeted review, we provide brief historical accounts of the main classes of psychoactive drugs and discuss several foundational total syntheses that ultimately provide the groundwork for producing these molecules in academic, industrial, and clandestine settings.
- 17 January 2018
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 9 (10) , 2307-2330
The DARK Side of Total Synthesis: Strategies and Tactics in Psychoactive Drug Production
Humankind has used and abused psychoactive drugs for millennia. Formally, a psychoactive drug is any agent that alters cognition and mood. The term “psychotropic drug” is neutral and describes the entire class of substrates, licit and illicit, of interest to governmental drug policy. While these drugs are prescribed for issues ranging from pain management to anxiety, they are also used recreationally. In fact, the current opioid epidemic is the deadliest drug crisis in American history. While the topic is highly politicized with racial, gender, and socioeconomic elements, there is no denying the toll drug mis- and overuse is taking on this country. Overdose, fueled by opioids, is the leading cause of death for Americans under 50 years of age, killing ca. 64,000 people in 2016. From a chemistry standpoint, the question is in what ways, if any, did organic chemists contribute to this problem? In this targeted review, we provide brief historical accounts of the main classes of psychoactive drugs and discuss several foundational total syntheses that ultimately provide the groundwork for producing these molecules in academic, industrial, and clandestine settings.
- 28 March 2017
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 69 (7) , 907-916
Retracted: The antiproliferative and apoptotic effects of apigenin on glioblastoma cells
Objectives. Glioblastoma (GBM) is highly proliferative, infiltrative, malignant and the most deadly form of brain tumour. The epidermal growth factor re
- 28 March 2017
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 69 (7) , 907-916
Retracted: The antiproliferative and apoptotic effects of apigenin on glioblastoma cells
Objectives. Glioblastoma (GBM) is highly proliferative, infiltrative, malignant and the most deadly form of brain tumour. The epidermal growth factor re
- 1 May 2016
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 26 (10) , 2481-2488
Synthesis and characterization of a series of chiral alkoxymethyl morpholine analogs as dopamine receptor 4 (D4R) antagonists
- 1 May 2016
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 26 (10) , 2481-2488
Synthesis and characterization of a series of chiral alkoxymethyl morpholine analogs as dopamine receptor 4 (D4R) antagonists